AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNATM) constructs as gene regulatory and immunotherapeutic agents, announced that Gordon Beck, Ph.D., has joined AuraSense Therapeutics' executive leadership team as vice president of business development.
Prior to joining AuraSense Therapeutics, he spent 16 years at Hoffmann-La Roche, most recently as executive director global business development. The company also added Helen S. Kim, M.B.A. to its Board of Directors. Beck brings 19 years of experience working for pharmaceutical and biotechnology companies in business development and R&D.
Want to read more?
Subscribe to one of our monthly plans to continue reading this article.